Related references
Note: Only part of the references are listed.The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
David M. Jackman et al.
CLINICAL CANCER RESEARCH (2009)
Biomarker Discovery: Identification of a Growth Factor Gene Signature
A. Loboda et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
A Genomic Strategy to Elucidate Modules of Oncogenic Pathway Signaling Networks
Jeffrey T. Chang et al.
MOLECULAR CELL (2009)
The most important news at ASCO 2009
Vincent T. DeVita
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
Christine A. Pratilas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
High-resolution genomic and expression analyses of copy number alterations in breast tumors
Peter M. Haverty et al.
GENES CHROMOSOMES & CANCER (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents:: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
Helena Linardou et al.
LANCET ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Singular value decomposition-based regression identifies activation of endogenous signaling pathways in vivo
Zhandong Liu et al.
GENOME BIOLOGY (2008)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gene expression signature of human cancer cell lines treated with the Ras inhibitor salirasib (S-farnesylthiosalicylic acid)
Roy Blum et al.
CANCER RESEARCH (2007)
High-throughput oncogene mutation profiling in human cancer
Roman K. Thomas et al.
NATURE GENETICS (2007)
Cross platform microarray analysis for robust identification of differentially expressed genes
Roberta Bosotti et al.
BMC BIOINFORMATICS (2007)
被撤回的出版物: Genomic signatures to guide the use of chemotherapeutics (Retracted article. See vol. 17, pg. 135, 2011)
Anil Potti et al.
NATURE MEDICINE (2006)
被撤回的出版物: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer (Retracted Article. See vol 356, pg 201, 2007)
Anil Potti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Strategies for comparing gene expression profiles from different microarray platforms: Application to a case-control experiment
Marco Severgnini et al.
ANALYTICAL BIOCHEMISTRY (2006)
Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma
DJ Panka et al.
CLINICAL CANCER RESEARCH (2006)
Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis
C Sotiriou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
AH Bild et al.
NATURE (2006)
Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes
P Warnat et al.
BMC BIOINFORMATICS (2005)
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis
C Mascaux et al.
BRITISH JOURNAL OF CANCER (2005)
Targeting ras signalling pathways in cancer therapy
J Downward
NATURE REVIEWS CANCER (2003)
Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front
CP Paweletz et al.
ONCOGENE (2001)
Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer
TR Hughes et al.
NATURE BIOTECHNOLOGY (2001)
Share Paper
